ABSTRACT

Palm oil, the oil derived from palm fruit, is the major oil used for cooking in Nigeria. Palm oil has half of its fatty acids made up of saturated fatty acids and 43% made up of palmitic acid. The unrefined red palm oil is the form in which most Nigerians use palm oil and it is generally regarded safer for cardiovascular health than other branded vegetable oils. Although the overall contribution of palm oil to cardiovascular health is still controversial and subject to on-going research, the high concentration of saturated fatty acids in palm oil presents palm oil as detrimental oil to cardiovascular health since dietary saturated fatty acids is an important risk of cardiovascular disease.

Keywords: Palm oil; cardiovascular disease; palmitic acid; saturated fatty acid; Nigeria.

1. INTRODUCTION

Palm oil is an edible vegetable oil derived from the mesocarp of palm fruit of the oil palms, primarily the African oil palm *Elaeis guineensis* [1] and to a much lesser extent from the American oil palm *Elaeis oleifera* [2] and the Maripa palm *Attalea maripa*. [3] It is called Epo-pupa, Manja and Mmanu in the three most widely spoken Nigerian Languages. [4] The African oil palm (*Elaeis guineensis*) is native to west and southwest Africa, occurring between Angola and Gambia [5]. It is particularly abundant in Nigeria. Mature palms are single-stemmed, and can grow

*Corresponding author: E-mail: malachiseyi@gmail.com;*
well over 20 m tall. The leaves are pinnate, and reach between 3-5 m long. The flowers are produced in dense clusters; each individual flower is small, with three sepals and three petals. The palm fruit is reddish, about the size of a large plum, and grows in large bunches. Each fruit is made up of an oily, fleshy outer layer (the pericarp), with a single seed (the palm kernel), also rich in oil.

Although Nigeria, in the 1980s, has lost its dominant position as the world leading producer and exporter of palm oil, [6] palm oil still remains the main vegetable oil produced in Nigeria and it is consumed in all its regions. [7] Nigeria is currently the third largest global producer, behind Indonesia and Malaysia [6]. Palm oil production accounted for 1.5% of the national agricultural GDP in 2006. [8] Nigeria palm oil production output represented 3% of the world production in 2010 [6] and 55% of African output. [7] The output is however not enough to match the local consumption. Indeed, the national demand has grown faster than the domestic supply. [9] Consequently, Nigeria imports palm oil to satisfy the local demand. Nevertheless, Nigeria has a potential to increase its production through the application of improved processing methods and better marketing; since palm oil production in Nigeria is characterized by traditional processing methods which are energy sapping and low in efficiency [10].

Palm oil is used in Nigeria for food and non-food consumption. Domestic dietary use accounts for more than half of the palm oil consumed in Nigeria. [6] The traditionally extracted, unrefined oil, also called Technical Palm Oil (TPO), is the form in which most household use palm oil for cooking [7]. Consequently of the presence of carotenones, Technical Palm Oil is dark red in color and has a characteristic flavor. Hence, Nigerians call it red oil and it occupies an important position in the Nigerian cuisine. In fact, in most Nigeria communities, it is unethical to cook some dishes with any other edible oil but the red oil [11].

Although cardiovascular diseases typically affect older adults, its antecedents, notably atherosclerosis is evident early in life. Hence, primary prevention efforts are necessary from childhood. [12] Of the risk factors that can be modified to improve cardiovascular health is healthy dietary lipid. [13] Palm oil has about half of its fatty acid content made up for saturated fatty acids, [14] a condition that is rare among vegetable oils. Consumption of saturated fatty acids increases the serum level of low density lipoprotein (LDL) [15] and high density lipoprotein (HDL). [16] Also, The world health organization warns that saturated fat is a risk factor of cardiovascular diseases. [17] However, Due to the accustomed flavour of the unrefined red palm oil, Nigerians eat more palm oil than any other edible oil and it is erroneously regarded safer for cardiovascular health compared to branded vegetable oils which are manufactured from soybean, peanut, cottonseed, sunflower, olive and rapeseed. [18,19] The branded vegetable oils, as opposed to "red oil", are termed "white oil" in the Nigerian traditional markets and are considered less healthy for dietary consumption. This work therefore aims to provide evidences to debunk this erroneous claim.

2. CHEMICAL COMPOSITION OF PALM OIL

Palm oil has more than 95% of its content saponifiable. [20] This saponifiable fraction is made up of triacylglycerides which are fatty acids (acyl chains) attached to a glycerol backbone. [21] During extraction process, the triacylglycerides however attracts lipophilic but unsaponifiable cellular components which include tocopherols, tocotrienols, sterols, ubiquinones and pigments. [20] The major fatty acids contained in palm oil are myristic (14:0), palmitic (16:0), stearic (18:0), oleic (18:1) and linoleic (18:2). [14,22] The most concentrated fatty acid in palm oil is palmitic acid which makes up about 43% of the fatty acid in the oil and is more concentrated in palm oil than in any other vegetable oil. [22] Hence it got its name from palm oil. Unlike most other vegetable oils, palm oil has half its fatty acid content made up of saturated fatty acids [14]. Consequently, it is semi-solid at room temperature. Other notable highly saturated vegetable fats are palm kernel oil which has 81% of its fatty acids saturated, [23] Coconut oil which has 86% of its fatty acids saturated [23] and Shea butter which also has half of its fatty acids saturated. [24] The fatty acid profile of palm oil as presented by Sundram and Co-workers [20] is shown in Table 1.

Apart from very few free fatty acids, most of the fatty acids in palm oil exist as acyl groups attached to glycerol to form triacylglyceride molecule. Since different fatty acids are present in palm oil, different combinations of fatty acids
Table 1. Typical fatty acid profile (%) of palm oil

| Fatty acid name | Fatty acid chain length | Mean  | Range observed | Standard deviation |
|----------------|------------------------|-------|----------------|--------------------|
| Lauric         | 12:0                   | 0.3   | 0-1            | 0.12               |
| Myristic       | 14:0                   | 1.1   | 0.9-1.5        | 0.08               |
| Palmitic       | 16:0                   | 43.5  | 39.2-45.8      | 0.95               |
| Palmitoleic    | 16:1                   | 0.2   | 0-0.4          | 0.05               |
| Stearic        | 18:0                   | 4.3   | 3.7-5.1        | 0.18               |
| Oleic          | 18:1 (n-9)             | 39.8  | 37.4-44.1      | 0.94               |
| Linoleic       | 18:2 (n-6)             | 10.2  | 8.7-12.5       | 0.56               |
| Linolenic      | 18:3                   | 0.3   | 0-0.6          | 0.07               |
| Arachindic     | 20:0                   | 0.2   | 0-0.4          | 0.16               |

attached to the glycerol are possible. In palm oil, the most predominant combinations are POP and POO (P-palmitic acid, O-Oleic acid); each making up about 20% of the triacylglycerides in palm oil. The fully saturated triacylglycerides, predominantly tripalmitin, make up 7%-10% while the fully unsaturated triacylglycerides constitute 6 to 12% of the triacylglycerides in palm oil. The middle position (Sn-2 position) of the glycerol molecule is specifically for unsaturated fatty acids. Therefore, more than 85% of the unsaturated fatty acids are located in the Sn-2 position of the glycerol molecule [25].

The minor constituents of palm oil are of two classes. The first class consists of saponifiable free fatty acid and fatty acid derivatives, such as diacylglycerides, monoacylglycerides, phosphatides, esters and sterol derivatives. The second class consist of unsaponifiable but lipophilic compounds such as free sterols, hydrocarbons, tocopherols, triterpene alcohol, pigments, aliphatic alcohols, chlorophylls, carotenoids and volatile flavour components, such as aldehydes and ketones. [26] Free fatty acids, monoacylglycerides and diacylglycerides do not occur naturally in significant amounts except in palm oil from damaged fruits. Such oils would have undergone partial hydrolysis resulting in the production of free fatty acids, water and the partial glycerides (monoacylglycerides and diacylglycerides) [20].

Sterols make up a sizable portion of the unsaponifiables in vegetable oils. The content of sterol in palm oil is about 0.03% of its total composition. Plant sterols are generally termed phytosterols and are notably campesterol, sitosterol and stigmastanol. Cholesterol, though generally regarded as an animal sterol, is also found in plants. [27] Cholesterol makes up to 6.7% of the sterol fragment of palm oil. Other noticeable sterol in palm oil include Δ5-avenasterol (0.2-2.8%) Δ7-stigmasterol (0-2.8%) and Δ7-avenasterol (0-4%). [26] Palm oil contains a recognizable amount of vitamin E in the form of tocopherol and tocotrienol. Crude palm oil contains 600 to 1000 ppm of tocopherol and tocotrienols. [28] Palm oil, like tomatoes, carrots, pumpkins and many other fruits, but unlike other vegetable oils contains carotenoids which give it its red coloration. [29] Carotenoids are precursors of vitamin A with β-carotene having the highest pro-vitamin A activity. [30] Palm oil has 15 times more Retinol Equivalents than carrot and 300 times more than tomato. There are about 13 different carotenoids in crude palm oil, all of which amounts to a concentration of about 500-700ppm. Alpha-carotene and Beta-carotene however make up more than 80% of the total carotenoids in palm oil. [31] Table 2 gives the composition of unsaponifiable fraction of palm oil as presented by Sundram [32].

3. CARDIOVASCULAR DISEASE

Cardiovascular disease refers to a class of diseases that affect the cardiovascular system, [33] principally cardiac disease, vascular diseases of the brain and kidney, and peripheral arterial disease. [34] The causes of cardiovascular diseases are diverse but atherosclerosis and hypertension are the most common. Also, aging increases the risk of cardiovascular diseases, even in healthy asymptomatic individual. [35] Types of cardiovascular diseases include: Coronary artery disease, Cardiomyopathy, Hypertensive heart disease, Heart failure Pulmonary heart disease, Cardiac dysrhythmias, Inflammatory heart diseases which are Endocarditis, Inflammatory cardiomegaly and Myocarditis, Valvular heart disease, Cerebrovascular disease, Peripheral arterial disease, Congenital heart disease and Rheumatic heart disease.
Cardiovascular diseases are the leading cause of global death [36] and are projected to remain the single leading cause of death till 2030. [37] Cardiovascular diseases were responsible for 17.5 million deaths in 2012, representing 31% of all global deaths. [38] Mortality due to cardiovascular diseases, according to World Bank analysis, has been declining in many high-income countries since the 1970s. [39,40] Conversely, cardiovascular disease and the consequent deaths have increased at a fast rate in low- and middle-income countries. [41] Over 80% of Cardiovascular deaths now take place in low- and middle-income countries. [36] Nigeria, like other middle-income countries, [42] is witnessing a general increase in deaths due to cardiovascular diseases [43-45].

Cardiovascular diseases are multi-factorial and several risk factors have been identified. These risk factors include: age, gender, unhealthy diet, physical inactivity, family history of cardiovascular disease, excessive alcohol consumption, tobacco use, obesity, raised blood sugar (diabetes mellitus), raised blood pressure (hypertension), raised blood cholesterol (hyperlipidemia), psychosocial factors, poverty and low educational status and air pollution. [38, 46-48] Although the individual contribution of these risk factors to the progression but not necessarily onset of cardiovascular disease varies considerable between different communities and ethnic groups, the overall contribution of these risk factors are very consistent. [49] While some of these risk factors such as gender, age or family history, are immutable; many important cardiovascular risk factors are modifiable by social change, lifestyle change, drug treatment and prevention of hyperlipidemia, hypertension, and diabetes.

### 3.1 Cardiovascular Diseases and Saturated Fat

Mainstream heart-health, government, and medical communities including the American Dietetic Association, [50] the World Health Organization, [51] the Dietitians of Canada, [50] the British Heart Foundation, [52] the British National Health Service, [53] the World Heart Federation [54] and the European Food Safety Authority [55] advise that saturated fat is a risk factor for cardiovascular disease. However, there are studies in recent times whose results suggest otherwise [56,57]. In 2014, a systematic review and meta-analysis of 72 published studies, totaling 530,525 participants, looked at observational studies of measured fatty acid levels in the blood, observational studies of dietary intake of fatty acids, and intervention studies of polyunsaturated fat supplementation. The authors of the review concluded that low consumption of saturated fatty acids and high consumption of polyunsaturated fatty acids is not clearly supported as a guideline for reducing the risk of cardiovascular diseases. [57] Similarly, a 2010 meta-analysis of prospective cohort studies supported by the National Dairy Council including 348,000 subjects found no statistically significant relationship between cardiovascular disease and dietary saturated fat. [56]

There have been serious criticisms of the meta-analyses whose results concluded that dietary saturated fat is not a risk factor of cardiovascular diseases. The work done by Chowdhury and co-worker [57] which concluded that “Current evidence does not clearly support cardiovascular guidelines that encourage high consumption of polyunsaturated fatty acids and low consumption of total saturated fatty acids” was criticized by Dr. Walter Willett of Department of Nutrition at Harvard School of Public Health who warns that there are serious omissions in the analysis and the conclusion is mis-leading. [58] Also, the 2010 meta-analysis that found no statistically significant relationship between dietary saturated fat and cardiovascular disease [46] has been

| Components | % | Mg/kg (in palm oil) |
|-----------|---|-------------------|
| Carotenoids | | |
| α-carotene | 36.2 | |
| β-carotene | 54.4 | |
| γ-carotene | 3.3 | 500 – 700 |
| Lycopene | 3.8 | |
| Xanthophylls | 2.2 | |
| Vitamin E | | |
| α-tocopherol | 28 | |
| α-tocotrienol | 29 | 500 – 800 |
| γ-tocotrienol | 28 | |
| Δ-tocotrienol | 14 | |
| Sterols | | |
| Cholesterol | 3 | |
| Campesterol | 22 | ~300 |
| Stigmasterols | 17 | |
| β-sitosterol | 56 | |
| Phosphatides | 500 – 1000 | |
| Total alcohols | | |
| Triterpenic alcohol | 80 | ~800 |
| Aliphahtic alcohol | 20 | |
3.2 Palm Oil and Cardiovascular Disease

The overall contributions of palm oil to cardiovascular health are controversial and subject to ongoing research. While several studies have linked palm oil with increase risk of cardiovascular diseases [72] and consequently deaths, [73] some other research works maintained that palm oil is not linked to the risk of cardiovascular disease. [74] Some studies even concluded that palm oil improve cardiovascular health. [75] Also, while some studies concluded that palm oil is not a safe substitute for hydrogenated fat (trans fat) because palm oil results in adverse changes in the blood concentrations of apolipoprotein B and LDL cholesterol just as trans fat does, [76,77] others argue that palm oil is an acceptable replacement for trans fat [78].

However, considering the fatty acid profile of palm oil, half of its fatty acids are saturated. [14,22] This is much unlike most vegetable oils including rapeseed oil, corn oil, cotton seed oil, olive oil, peanut oil, safflower oil and soybean oil; all of which are made up of less than 20% saturated fat. [79] A well refined branded vegetable oil manufactured from these oils will therefore have a lower percentage of saturated fatty acids hence a less risk to cardiovascular health. Dietary saturated fatty acid has been implicated in the onset and progression of cardiovascular diseases [61-71].

Shea butter, a vegetable fat that is also used as dietary lipid in Nigeria, though also has half of its fatty acid saturated, [80,81] has been reported to reduce circulatory cholesterol concentrations in experimental animal. [82-84] This paradox can be explained by the fact that the saturated fatty acid concentration of palm oil is constituted majorly of palmitic acid (16:0), [14] while that of Shea butter is constituted majorly of stearic acid (18:0). [24] Different saturated fatty acids contribute differently to cardiovascular disease. In epidemiological and clinical studies, Stearic acid (18:0) was found to be associated with lower LDL compared to any other saturated fatty acid. [85] Also, an isotope labeling study in humans [86] concluded that the fraction of dietary stearic acid (18:0) that oxidatively desaturates to oleic acid (18:1) is 2.4 times higher than the fraction of palmitic acid (16:0) analogously converted to palmitoleic acid (16:1). These demonstrate that dietary palmitic acid (16:0) contributes to progression of cardiovascular disease than stearic acid (18:0).

Sundram and co workers [20] claim that the saturated fatty acid content of palm oil is balanced by its unsaturated fatty acids and concluded that there is no risk of cardiovascular diseases related to palm oil consumption. However, it has been demonstrated that while there is no clear health benefit of replacing saturated fatty acids with starchy foods [65], replacement with unsaturated fatty acids reduced the risk of cardiovascular disease. A decrease as slight as 5% in dietary saturated fatty acid amounted to 13% decrease in cardiovascular disease occurrence and 26% decrease in deaths. [66] Replacing “red oil” with “white oil” in a Nigerian diet will decrease saturation by about 30% which will definitely be a positive move toward cardiovascular health. Also, a typical Nigerian diet is characterized by the presence of red meat (usually beef) [87,88] which promotes cardiovascular disease. [89,90] Hence, the need to reduce other cardiovascular risk factors in Nigerian diet.

The unsaponifiables of vegetable oils, usually sterols, vitamin E and triterpene alcohols [31,81,91-94] are generally appreciated for health benefits including antioxidant, anti-cancer and circulatory cholesterol reducing abilities. [95-98] The presence of these unsaponifiables in palm oil however does not give an edge to palm oil since these unsaponifiables are present in most vegetable oils. [31,81,91-94] A particular unsaponifiable component that is exclusive to palm oil amongst vegetable oil is carotenoid. [29] The overall contribution of carotenoids to the progression of cardiovascular disease is however under controversial with some studies reporting disadvantageous relationship. [99]

4. CONCLUSION

Consequence of having half of its fatty acid saturated and high level of palmitic acid, palm oil is no safer dietary oil compared to branded vegetable oils manufactured from soybean, peanut, cotton, sunflower, olive and rape.
5. RECOMMENDATION

Since it is clearer that vegetable oils from different sources contribute differently to cardiovascular health, the National Agency for Food and Drug Administration and Control (NAFDAC) should disallow the use of the generic terms “vegetable fat” or “vegetable oil” in the ingredients list of packaged foods in Nigeria. Food producers in Nigeria, like in the European Union, [100] should be required to list the specific type of vegetable oil or fat used, including palm oil. Also consumers should be made aware of the risk involved with consumption of palm oil.

ACKNOWLEDGEMENTS

A huge thank you goes to Mr. B. I. Oladapo for his encouragement and counsels. The love and care of Mrs. K. K. Oladapo cannot be over-appreciated.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

1. Reeves JB, Weihrauch JL. Composition of foods: fats and oils. Consumer and Food Economics Institute. Agriculture handbook 8-4. Washington, D.C.: U.S. Dept. of Agriculture, Science and Education Administration, p. 4. OCLC 5301713; 1979.
2. Anonymous. Replanting diseased oil palm areas with Elaeis oleifera X E. guineensis hybrids at “La Arenosa” Estate in Colombia. Oil Palm News. 1974;18:1-6.
3. Andrew H, Galeano G, Bernal R. Field guild to the palms of America. Priceton, New Jersey: Priceton University Press. ISSN 0-691-08537-4; 1995.
4. Gordon RG. Ethnologue: Languages of the World, Fifteenth edition. Jr. (ed.) Dallas, Tex.: SIL International; 2005. Available: http://www.ethnologue.com/
5. Collins Guide to Tropical Plants, ISBN 0-00-219112-1.
6. UN. Food and Agriculture Organization (FAO) Trade data base, Production Data Base; 2012. Available: http://faostat.fao.org/
7. Gourichon H. Analysis of incentives and disincentives for palm oil in Nigeria.
8. Nwafor M, Diao X, Alpuerto VA. 2006 Social Accounting Matrix (SAM) for Nigeria: Methodology and Results. Washington, D. C.: International Food Policy Research Institute (IFPRI) (datasets); 2010. Available: http://www.ifpri.org/dataset/2006-social-accounting-matrix-nigeria-methodology-and-results
9. Foundation for partnership in the Niger Delta (PIND) Palm oil value chain analysis in the Niger Delta; 2011.
10. Olagunju FI. Economics of palm oil processing in Southwestern Nigeria. International Journal of Agricultural Economics and Rural Development. 2008; 1(2):69-77.
11. Anthonio HO, Isoun M. Nigerian Cookbook. Macmillan, Lagos; 1982.
12. McGill HC, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation. 2008;117(9): 1216–27. DOI:10.1161/CIRCULATIONAHA.107.717033. PMID 18316498.
13. Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ (Clinical research ed.). 2013;346:e8707. DOI: 10.1136/bmj.e8707. PMID 23386268.
14. Cottrell RC. Introduction: nutritional aspects of palm oil. The American Journal of Clinical Nutrition. 1991;53(4 Suppl): 989S–1009S. PMID 2012022.
15. Medical nutrition & disease: A case-based approach. p. 202. ISBN 0-632-04658-9.
16. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb. 1992;12(8):911–9. DOI: 10.1161/01.ATV.12.8.911. PMID 136252.
17. Joint WHO/FAO Expert Consultation Diet, Nutrition and the Prevention of Chronic Diseases (WHO technical report series 916). World Health Organization. pp. 81–94. ISBN 92-4-120916-X; 2003.
18. Okpuzor J, Okochi VI, Ogbunugafor HA, Ogbonna S, Fagbayi T, Obidiegwu C. Estimation of cholesterol levels in different brands of vegetable oil. Pakistan Journal of Nutrition. 2009;8:57-62.

19. Ayaji OB, Malachi OI. Comparative study of the fatty acid profiles of the vegetable oil brands consumed in Nigeria. Journal of Advances in Biology and Biotechnology. In press; 2015.

20. Sundram K, Sambanthamurthi R, Tan YA. Palm fruit chemistry and nutrition. Asia Pacific J Clin Nutr. 2003;12(3):355-362.

21. Nelson DL, Cox MM. Lehninger. Principles of biochemistry. W. H. Freeman Publisher. 2008;5(10):346.

22. Siew WL. Analysis of palm and palm kernel oils. In: Basiron Y, Jalani BS, Chan KW, eds. Advances In Oil Palm Research. Kuala Lumpur: Malaysian Palm Oil Board. 2000;968-1035.

23. Harold M. On food and cooking: The science and lore of the kitchen, Scribner, edition; 2004. ISBN 978-0-684-80001-1.

24. Maranz S, Wiesman Z, Bisgaard J, Bianchi G. Germplasm resources of Vitellaria paradoxa based of variations in fat composition across the species distribution range. Agroforestry Systems (in Cooperation with ICRAF). 2004;60:71.

25. Kifli H. Studies on palm oil with special reference to interesterification. PhD Thesis, University of St, rews, United Kingdom; 1981.

26. Sambanthamurthi R, Sundram K, Tan YA. Chemistry and biochemistry of palm oil. Progress in Lipid Research, 2000;507-558.

27. Behrman EJ, Venkat G. Cholesterol and plants. J Chemical Edu. 2005;82:1790-1793.

28. Sundram K, Nor RM. Analysis of tocotrienols in different sample matrixes by HPLC. In (ed. D. Armstrong) Methods in Molecular Biology: Oxidative Stress Biomarkers and Antioxidant Protocols. Humana Press Inc. Totowa, New Jersey, USA. 2001;186:221-232.

29. Bonnie TYP, Choo YM. Valuable minor constituents of commercial red palm olein: carotenoids, vitamin E, ubiquinones and sterols. Journal of Oil Palm Research. 2000;12(1):14-24.

30. Arnun SDV. Vitamin A in Kirk-Othmer encyclopedia of chemical technology (45). New York: John Wiley. 1998;99-107. DOI: 10.1002/0471238961.22092001011181 421.a01. ISBN 0-471-23896-1.

31. Yap SC, Choo YM, Ooi CK, Ong ASH, Goh SH. Quantitative analysis of carotenines in the oil from different palm species. Elaeis. 1997;3:309-378.

32. Sundram K. Palm oil: Chemistry and nutrition updates. Malaysian Palm Oil Board (MPOB), P.O. Box 10620, 50720 Kuala Lumpur, Malaysia; 2003.

33. Anthea M, Hopkins J, McLaughlin CW, Johnson S, Warner MQ, LaHart D, et al. Human biology and health. Englewood Cliffs, New Jersey: Prentice Hall; 1993. ISBN 0-13-981176-1.

34. Kelly BB. Promoting cardiovascular health in the developing world: A critical challenge to achieve global health. Institute of Medicine; Fuster, Valentin. Washington, D.C: National Academies Press; 2010. ISBN 0-309-14774-3.

35. Dantas AP, Jimenez-Altayo F, Vila E. Vascular aging: Facts and factors. Frontiers in Vascular Physiology. 2012;3 (325):1–2. DOI: 10.3389/fphys.2012.00325. PMC: 3429093. PMID 22934073.

36. World Health Organization Global status report on noncommunicable diseases 2010. Gevena, World Health Organization; 2011.

37. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.

38. World Health Organization. Cardiovascular diseases (CVDs). Media centre. Available: http://www.who.int/mediacentre/factsheets/fs317/en/

39. Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease prevention and control. World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization; 2011. ISBN 978-92-4-156437-3.

40. Kelly BB. Countries, committee on preventing the global epidemic of cardiovascular disease: Meeting the challenges in developing; Fuster, Board on Global Health; Valentin; Academies; Institute of Medicine of the National (2010). Promoting cardiovascular health in the developing world: a critical challenge to achieve global health. Washington, D.C.: National Academies Press. pp. Chapter 2; 2010. ISBN 978-0-309-14774-3.

41. Finegold JA, Asaria F, Francis DP. Mortality from ischaemic heart disease by country, region, and age: Statistics from
World Health Organisation and United Nations. International Journal of Cardiology. 2012;168(2):934–945. DOI: 10.1016/j.ijcard.2012.10.046. PMID: 23218570.

42. Central Intelligence Agency. Nigeria. World Fact Book; 2014. Available:Https://www.cia.gov/library/publications/the-world-factbook/goes/ni.html

43. Mukadas AO, Misbau U. Incidence and patterns of cardiovascular disease in north western Nigeria. Niger Med J. 2009;50:55-57.

44. Ojikutu RK. Prevalence of cardiovascular disease in the Lagos State, Nigeria. Ghana Journal of Development Studies. 2009; 6(2). DOI: 10.4314/gjds.v6i2.61388. ISSN: 0855-6768

45. Nwaneli CU. Changing trend in coronary heart disease in Nigeria. Afrimedic Journal. 2010;1(1):1-4.

46. Howard BV, Wylie-Rosett J. Sugar and cardiovascular disease: A statement for healthcare professionals from the Committee on Nutrition of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation. 2002;106(4):523–7. DOI:10.1161/01.cir.0000019552.77778.04. PMID: 12135957.

47. Micha R, Michas G, Mozaffarian D. Unprocessed red and processed meats and risk of coronary artery disease and type 2 diabetes—an updated review of the evidence. Current Atherosclerosis Reports. 2012;14(6):515–24. DOI: 10.1007/s11883-012-0282-8. PMC: 3483430. PMID: 23001745.

48. Finks SW, Airee A, Chow SL, Macaulay TE, Moranville MP, Rogers KC, et al. Key articles of dietary interventions that influence cardiovascular mortality. Pharmacotherapy. 2012;32(4):e54–87. DOI: 10.1002/j.1875-9114.2011.01087.x. PMID 22392596

49. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438): 937–52. DOI: 10.1016/S0140-6736(04)17018-9. PMID: 15364185.

50. Kris-Etherton PM, Innis S. Position of the American Dietetic Association and Dietitians of Canada: Dietary fatty acids. J Amer Dietetic Assoc. 2007;107(9):1599–1611 [1603]. PMID: 17936958.

51. Joint WHO/FAO Expert Consultation Diet, Nutrition and the Prevention of Chronic Diseases (WHO technical report series 916). World Health Organization. 2003; 81–94. ISBN 92-4-120916-X.

52. British Heart Foundation. Fats Explained. Available:http://www.bhf.org.uk/heart-health/preventing-heart-disease/healthy-eating/fats-explained/

53. "Eat less saturated fat". National Health Service. Available:http://www.nhs.uk/livewell/goodfood/pages/eat-less-saturated-fat.aspx

54. World Heart Federation. Cardiovascular disease risk factors. Available:http://www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease-risk-factors

55. Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. European Food Safety Authority. Available:http://www.efsa.europa.eu/en/efsajournal/pub/1461.htm

56. Siri-Tarino PW, Sun Q, Hu FB, Krauss RM. Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease. Amer J Clin Nutr. 2010;91(3):535–546. DOI: 10.3945/ajcn.2009.27725. PMC 2824152.PMID 20071648.

57. Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk. Annals of Internal Medicine. 2014;160(6): 398–406. DOI: 10.7326/M13-1788. PMID 24723079.

58. Willett W, Sack F, Stampfer M. Dietary fat and heart disease study is seriously misleading. Harvard School of Public Health; 2014. Available:http://www.hsph.harvard.edu/nutritionsource/2014/03/dietary-fat-and-heart-disease-study-is-seriously-misleading/

59. Scarborough P, Rayner M, van Dis I, Norum K. Meta-analysis of effect of saturated fat intake on cardiovascular disease: Overadjustment obscures true associations. The American Journal of Clinical Nutrition. 2010;92(2):458–459.
60. Stampler J. Diet-heart: a problematic revisit. Am. J. Clin. Nutr. 2010;91(3):497–9. DOI: 10.3945/ajcn.2010.29540. PMID 20534750.

61. Stewart TA. Review of dietary intervention studies: effect on coronary events and on total mortality. Australian and New Zealand Journal of Medicine. 1994;24(1):98–106. DOI: 10.1111/j.1445-5994.1994.tb04444.x. PMID 8002875.

62. Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ (Clinical research ed.). 2013;346:e8707. DOI: 10.1136/bmj.e8707. PMID: 23386268.

63. Ursula S, Lotte L, Tine T, Thorhallur H, Ulf R, Matti U, et al. Effect of the amount and type of dietary fat on cardiometabolic risk factors and risk of developing type 2 diabetes, cardiovascular diseases, and cancer: a systematic review. Food & Nutrition Research. 2014;58. DOI: 10.3402/fnr.v58.25145.

64. Mozaffarian D, Micha R, Wallace SK, Martijn B, et al. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: A systematic review and meta-analysis of randomized controlled trials. PLoS Medicine. 2010;7(3):1–10. DOI: 10.1371/journal.pmed.1000252. ISSN 1549-1277. PMC 2843598. PMID 20351774.

65. Hooper L, Summerbell CD, Thompson R, Sills D, Roberts FG, Moore H, et al. Reduced or modified dietary fat for preventing cardiovascular disease. The Cochrane Library. 2011;7:CD002137. DOI: 10.1002/14651858.CD002137.pub2. PMC 4163969. PMID 21735388.

66. Jakobsen MU, O'Reilly EJ, Heitmann BL, Pereira MA, Bälter K, Fraser GE, et al. Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. The American Journal of Clinical Nutrition. 2009;89(5):1425–32. DOI: 10.3945/ajcn.2008.27124. PMC: 2676998. PMID: 19211817.

67. Murray S, Jody M. Dietary fat and coronary heart disease: Summary of evidence from prospective cohort and randomised controlled trials. Annals of nutrition & metabolism. 2009;55(1–3):173–U287. DOI: 10.1159/000229902. ISSN: 0250-6807. PMID: 19752542.

68. Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJL, et al. Hales, Simon, ed. The preventable causes of death in the United States: Comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Medicine. 2009;6(4):e1000058. DOI: 10.1371/journal.pmed.1000058. ISSN: 1549-1277. PMC: 2667673. PMID: 19399161.

69. Chanu B. Primary dietetic prevention of ischaemic heart disease. Archives des Maladies du Coeur et des Vaisseaux. 2003;96(6): 21–25. ISSN 0003-9683.

70. Hu FB, Stampfer MJ. Nut consumption and risk of coronary heart disease: a review of epidemiologic evidence. Current Atherosclerosis Reports. 1999;1(3):204–209. DOI: 10.1007/s11883-999-0033-7. PMID 11122711.

71. Van Horn L, McCoin M, Kris-Etherton PM. Burke F, Carson JA, Champagne CM, et al. The evidence for dietary prevention and treatment of cardiovascular disease. Journal of the American Dietetic Association. 2008;108(2):287–331. DOI: 10.1016/j.jada.2007.10.050. ISSN 0002-8223. PMID 18237578.

72. Kabagambe EK, Baylin A, Ascherio A, Campos H. The type of oil used for cooking is associated with the risk of nonfatal acute myocardial infarction in Costa Rica. Journal of Nutrition (135 ed.) (Journal of Nutrition), 2005;135(11):2674–2679. PMID 16251629.

73. Chen BK, Seligman B, Farquhar JW, Goldhaber-Fiebert JD. Multi-Country analysis of palm oil consumption and cardiovascular disease mortality for countries at different stages of economic development: 1980-1997. Globalization and Health. 2011;7(1):45. DOI: 10.1186/1744-8603-7-45. PMC: 3271960. PMID: 22177256.

74. Sundram K, Hornstra G, Houwelingen AGV, Kester ADM. Replacement of dietary fat with palm oil: effect on human serum lipids, lipoproteins and apolipoproteins. Br J Nutr. 1992;68:677-692.
75. Mukherjee S, Mitra A. Health effects of palm oil (Report). Indian Institute of Technology. 2009;199. Available: http://www.krepublshers.com/02-Journals/JHE/JHE-26-0-000-09-Web/JHE-26-3-000-09-Abst-PDF/JHE-26-3-197-09-1776-Mukherjee-S.JHE-26-3-197-09-1776-Mukherjee-S-Tt.pdf

76. Vega-López S, Ausman LM, Jalbert SM, Erkila AT, Lichtenstein AH. Palm and partially hydrogenated soybean oils adversely alter lipoprotein profiles compared with soybean and canola oils in moderately hyperlipidemic subjects. American Journal of Clinical Nutrition (American Society for Nutrition). 2006; 84(1):54–62. PMID 16825681.

77. Bliss RM. Palm Oil Not a Healthy Substitute for Trans Fats; 2009. Available: http://www.ars.usda.gov/is/pr/2009/090415.htm

78. Hayes KC, Pronczuk A. Replacing trans fat: the argument for palm oil with a cautionary note on interesterification (Report). Journal of the American College of Nutrition; 2010. PMID 20823487.

79. Nutrient database, Release 24. United States Department of Agriculture. Available: http://ndb.nal.usda.gov/

80. Davrieux F, Allal F, Piombo G, Kelly B, Okulo JB, Thiam M, et al. Near infrared spectroscopy of high-throughput characterization of Shea tree (Vitellaria paradoxa) nut fat profiles. Journal of Agricultural and food Chemistry. 2010;58:7811-7819.

81. Maranç S, Wiesman Z. Influence on the tocopherol content of shea butter. J. Agric. Food Chem. 2004;52:2934-2937.

82. Malachi OI, Ajayi OB, Akomolafe SF. Effects of shea butter based diet on hepatic and renal enzymes and plasma lipid profile in albino rats. Advances in Biochemistry. 2014;2(5):80-84. DOI: 10.11648/j.ab.20140205.15

83. Akinwale A, Modu S, Maisartu MA, Zainab MA, Bilkisu UMA. Effect of feeding various concentrations of shea oil on some biochemical parameters in normal albino rat. Bulletin of Environment, Pharmacology & Life Sciences. 2012;1(2):14-17.

84. Tholstrup T, Marckmann P, Jespersen J, Sandström B. Fat high in stearic acid favorably affects blood lipids and factor VII coagulant activity in comparison with fats high in palmitic acid or high in myristic and lauric acids. Am J Clin Nutr. 1994;59(2):371-377.

85. Hunter JE, Zhang J, Kris-Etherton PM. Cardiovascular disease risk of dietary stearic acid compared with trans, other saturated, and unsaturated fatty acids: A systematic review. Amer J Clin Nutr. 2009;91(1):46–63. DOI: 10.3945/ajcn.2009.27661. PMID 19939984.

86. Emken EA. Metabolism of dietary stearic acid relative to other fatty acids in human subjects. Amer J Clin Nutr. 1994;60(6):1023S–1028S. PMID 7977144.

87. Hudgens J. Rough Guide to West Africa. City: Rough Guides Limited. P. 1007; 2004. ISSN 1-84353-118-6.

88. Bernard B, Bertrand G, Bernard C. Demand for farm animal products in Nigeria: An opportunity for Sahel Countries. Revue Grain De sel: Special Issue: Nigeria; 2011.

89. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, et al. Intestinal microbiota metabolism of L -carnitine, a nutrient in red meat, promotes atherosclerosis. Nature Medicine. 2013; 19:576–585. DOI: 10.1038/nm.3145

90. Renata M, Georgios M, Dariush M. Unprocessed red and processed meats and risk of coronary artery disease and Type 2 diabetes – An updated review of the evidence. Current Atherosclerosis Reports. 2012;14(6):515–524. DOI: 10.1007/s11883-012-0282-8. ISSN 1523-3804.

91. Itoh T, Tamura T, Matsumoto T. Sterols, Methylsterols, and Triterpene Alcohols in three Theaceae and some other vegetable oils. Lipids. 1974;9:173-184.

92. Lercker G, Rodriguez-Estrada MT. Chromatographic analysis of unsaponifiable compounds of olive oils and fat-containing food. J. Chromatogr. 2000; A881:105-129.

93. Lippiello L, Nardo JV, Harlan R, Chiou T. Metabolic Effects of Avocado/Soy Unsaponifiables on Articular Chondrocytes. Evid. Based Complement. Alternat. Med. 2008;5(2):191-197.

94. Di Vincenzo D, Maranç S, Serraiocco A, Vito R, Wiesman Z, Bianchi G. Regional variation in shea butter lipid and triterpene composition in four African Countries. J. Agric. Food Chem. 2005;53:7473-7479.
95. Herrera E, Barbas C. Vitamin E: action, metabolism and perspectives. Journal of Physiology and Biochemistry. 2001;57(2):43-56. DOI: 10.1007/BF3179812. PMID 1157997.
96. Paiva SA, Russell RM. β-Carotene and other carotenoids as antioxidants. J. Am. Coll. Nutr. 1999;18(5):426-433.
97. Pollak OJ. Reduction of blood cholesterol in man. Circulation. 1953;7(5):702–6. DOI: 10.1161/01.CIR.7.5.702. PMID 13042924
98. Tilvis RS, Miettinen TA. Serum plant sterols and their relation to cholesterol absorption. The American Journal of Clinical Nutrition. 1986;43(1):92–7. PMID 3942097.
99. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. The New England Journal of Medicine. 1996;334(18):1150-1155.
100. New EU Food Labeling Rules Published (Report). USDA Foreign Agricultural Service. Available:http://gain.fas.usda.gov/Recent%20GAIN%20Publications/NEW%20EU%20FOOD%20LABELING%20RULES%20PUBLISHED_Brussels%20USEU_EU-27_1-12-2012.pdf